Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss due to certain medical conditions. It has a low side effect profile and is safe to administer in most instances. Anaphylaxis cases due to intravenous TXA have been reported in the literature. We report the first pediatric case of anaphylaxis due to the use of nebulized TXA. A 2-year-old boy with cerebral palsy, epilepsy, and tracheostomy was hospitalized with pneumonia. On the fourth day of hospitalization, the patient started bleeding from the trachea. Nebulized TXA was started to reduce tracheal bleeding. Anaphylaxis developed 5 min after administration of nebulized TXA. Subsequently, the patient was successfully treated with adrenaline, intravenous fluids, antihistamines, and steroids. Nebulized TXA is increasingly used off-label. Although it has a safe profile, side effects such as anaphylaxis may occur rarely. It is essential to recognize the symptoms of anaphylaxis when using nebulized TXA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/ped.2024.0035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in the study of nebulized tranexamic acid for pulmonary hemorrhage.
Eur J Clin Pharmacol
November 2024
Department of Cardiology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- Pulmonary hemorrhage is a serious condition that causes blood to leak into the lungs, leading to severe breathing issues, and nebulized tranexamic acid (TXA) shows promise as a treatment option due to its targeted effects and fewer side effects.
- A thorough search of multiple research databases revealed studies on nebulized TXA for pulmonary hemorrhage, including data from two randomized controlled trials, six case series, and nine case reports.
- The findings indicate that nebulized TXA effectively manages bleeding with a dosage of 500 mg/5 ml given 3-4 times daily, showing safety with minimal side effects, mainly local reactions that are easily treated.
Nebulized tranexamic acid for treatment of post-tonsillectomy bleeding: a systematic review and meta-analysis.
Eur Arch Otorhinolaryngol
October 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Hera General Hospital, Makkah, Saudi Arabia.
Article Synopsis
- The study investigates the use of nebulized tranexamic acid (TXA) for treating post-tonsillectomy bleeding (PTB), a common complication leading to emergency department visits.
- By systematically reviewing nine studies, the researchers assessed the effectiveness and safety of nebulized TXA, finding a lower reoperation rate for those treated with TXA compared to those who weren't.
- The results suggest that nebulized TXA is a safe and effective treatment for PTB, but more extensive research is needed to confirm these findings.
First Reported Case of Anaphylaxis to Nebulized Tranexamic Acid in a Pediatric Patient: A Rare but Critical Event.
Pediatr Allergy Immunol Pulmonol
July 2024
Department of Pediatrics, Ministry of Health Konya Dr Ali Kemal Belviranlı Obstetrics and Gynecology Hospital, Konya, Turkey.
Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss due to certain medical conditions. It has a low side effect profile and is safe to administer in most instances. Anaphylaxis cases due to intravenous TXA have been reported in the literature.
View Article and Find Full Text PDFTreatment of Post-Tonsillectomy Hemorrhage With Nebulized Tranexamic Acid: Initial Investigation of a Novel Therapeutic Modality.
Ann Otol Rhinol Laryngol
August 2024
Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Chicago, IL, USA.
Objectives: The use of nebulized tranexamic acid (TXA) in massive pulmonary hemorrhage is well-described. Published utilization in post-tonsillectomy bleeding (PTB) is limited to a single case. This study examines whether TXA resulted in change of operative intervention necessity and narcotic utilization.
View Article and Find Full Text PDFEffectiveness of Nebulized Tranexamic Acid in Patients with Moderate-to-Massive Hemoptysis at a Tertiary Academic Medical Center.
J Aerosol Med Pulm Drug Deliv
December 2023
Harvard Medical School, Boston, Massachusetts, USA.
The management of severe hemoptysis mainly consists of invasive interventional procedures, including angiographic bronchial artery embolization, various endobronchial interventions, and sometimes surgery. However, there are limited effective noninvasive medical therapies available. The objective of this analysis was to evaluate the effectiveness and safety of nebulized tranexamic acid (TXA) administration compared with conventional management in patients with hemoptysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!